Olaparib Improves PFS in BRCA-mutant Breast Cancer

Share this content:
Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.
Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.

Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative, BRCA1/2 mutated metastatic breast cancer, according to a press release from AstraZeneca.1

The ongoing international, open-label, phase 3 OLYMPIAD trial (ClinicalTrials.gov Identifier: NCT02000622) randomly assigned 302 patients with metastatic breast cancer who harbored deleterious or suspected deleterious germline BRCA1/2 mutations to receive olaparib orally twice daily or physician's choice of capecitabine, vinorelbine, or eribulin.

Patients treated with olaparib demonstrated a significant and clinically meaningful improvement in progression-free survival vs those who received standard of care chemotherapy. Initial findings indicate that the safety of olaparib was consistent with previous studies.

This study is the first randomized trial evaluating the efficacy and safety of a PARP inhibitor to show positive results beyond ovarian cancer.

RELATED: Impact of Antidiabetic Agents on Breast Cancer Risk in Older Women

Olaparib is approved by the U.S. Food and Drug Administration as monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have received at least 3 prior lines of chemotherapy.

Reference

  1. Lynparza meets primary endpoint in phase III trial in BRCA-mutated metastatic breast cancer [news release]. Wilmington, DE: AstraZeneca; February 17, 2017. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/lynparza-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-17022017.html. Accessed February 21, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters